RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights GlobeNewswire November 06, 2025 – Initiated prestIgE Phase 2b trial of ozureprubart in food allergy – Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and Q12W dosing had comparable efficacy and safety to omalizumab […]
LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) — Evotrex, a California-based company transforming the future of outdoor adventure through bold innovation, today announced its emergence from stealth mode with $16 million in Pre-A funding. The company is transforming what it means to live and travel off-grid by going beyond electric and into a new era
Healthcare Minus the Headache: RokketMed, A Solution to Finding the Care That Counts Turnkey San Francisco Platform Aims to Help All Employers and Workers GlobeNewswire November 06, 2025 SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) — In the face of mounting healthcare compliance complexity and an urgent need for accessible healthcare, San Francisco employers and
(NASDAQ:IOTR), Singapore, Nov. 06, 2025 (GLOBE NEWSWIRE) — iOThree Limited (Nasdaq: IOTR, the “Company”), today announced that the shareholders and the board of directors of the Company approved a one-for-ten reverse share split of the Company's issued and unissued ordinary shares (the “Ordinary Shares”), class A shares, and preferred shares. Beginning November 10, 2025, the
PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results GlobeNewswire November 06, 2025 PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company
(NYSE:OPHC), FT. LAUDERDALE, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) — OptimumBank Holdings, Inc. (NYSE American: OPHC), announced today that it will release its financial results for the third quarter ended September 30, 2025, before the market opens on Thursday, November 13, 2025. The Company's management team will host a conference call and live webcast that
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire November 06, 2025 NORWOOD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced it will be participating in the following investor conferences. Guggenheim's Second Annual Healthcare Innovation Conference in BostonFormat: Presentation
5th Annual BioTech Breakthrough Awards Program Honors World's Most Innovative Life Sciences and Biotechnology Companies Prestigious Annual Awards Program Celebrates Pioneering Breakthroughs Transforming Global Health, Research and Sustainability GlobeNewswire November 06, 2025 LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) — BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences
Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015 GlobeNewswire November 06, 2025 The issued patent provides intellectual property protection for ERAS-0015 and related compositions until at least 2043 Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) — Erasca,
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire November 06, 2025 WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2025 and